Fenwick, Latham Lead Scribe Therapeutics' $129M IPO
Early-stage biotechnology firm Scribe Therapeutics began trading publicly on Friday after raising $129 million in its upsized initial public offering steered by Fenwick & West LLP and Latham & Watkins LLP....To view the full article, register now.
Already a subscriber? Click here to view full article